nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP1A2—Imiquimod—skin cancer	0.109	0.144	CbGbCtD
Ondansetron—CYP2E1—Dacarbazine—skin cancer	0.0792	0.104	CbGbCtD
Ondansetron—CYP2C9—Vismodegib—skin cancer	0.0681	0.0897	CbGbCtD
Ondansetron—CYP1A2—Vemurafenib—skin cancer	0.0598	0.0787	CbGbCtD
Ondansetron—CYP3A4—Temozolomide—skin cancer	0.0571	0.0753	CbGbCtD
Ondansetron—CYP3A4—Imiquimod—skin cancer	0.0571	0.0753	CbGbCtD
Ondansetron—CYP2D6—Vemurafenib—skin cancer	0.0492	0.0649	CbGbCtD
Ondansetron—CYP1A2—Dacarbazine—skin cancer	0.0458	0.0603	CbGbCtD
Ondansetron—CYP3A4—Vismodegib—skin cancer	0.0396	0.0522	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0367	0.0484	CbGbCtD
Ondansetron—CYP3A7—Docetaxel—skin cancer	0.0367	0.0484	CbGbCtD
Ondansetron—CYP3A4—Vemurafenib—skin cancer	0.0313	0.0412	CbGbCtD
Ondansetron—CYP3A5—Docetaxel—skin cancer	0.0276	0.0363	CbGbCtD
Ondansetron—CYP1A2—Fluorouracil—skin cancer	0.0269	0.0354	CbGbCtD
Ondansetron—CYP2C9—Fluorouracil—skin cancer	0.0242	0.0319	CbGbCtD
Ondansetron—CYP3A4—Docetaxel—skin cancer	0.0107	0.0142	CbGbCtD
Ondansetron—Anaphylactic shock—Vemurafenib—skin cancer	0.000794	0.0033	CcSEcCtD
Ondansetron—Nervous system disorder—Vemurafenib—skin cancer	0.000779	0.00324	CcSEcCtD
Ondansetron—Skin disorder—Vemurafenib—skin cancer	0.000771	0.0032	CcSEcCtD
Ondansetron—Ill-defined disorder—Imiquimod—skin cancer	0.00077	0.0032	CcSEcCtD
Ondansetron—Agitation—Imiquimod—skin cancer	0.000763	0.00317	CcSEcCtD
Ondansetron—Angioedema—Imiquimod—skin cancer	0.000758	0.00315	CcSEcCtD
Ondansetron—Hepatocellular injury—Docetaxel—skin cancer	0.000757	0.00314	CcSEcCtD
Ondansetron—Injection site reaction—Docetaxel—skin cancer	0.000752	0.00312	CcSEcCtD
Ondansetron—Hypokalaemia—Temozolomide—skin cancer	0.000752	0.00312	CcSEcCtD
Ondansetron—Malaise—Imiquimod—skin cancer	0.000748	0.00311	CcSEcCtD
Ondansetron—Syncope—Imiquimod—skin cancer	0.000744	0.00309	CcSEcCtD
Ondansetron—Acute coronary syndrome—Bleomycin—skin cancer	0.000744	0.00309	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.000744	0.00309	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.000744	0.00309	CcSEcCtD
Ondansetron—Hypotension—Vemurafenib—skin cancer	0.000742	0.00308	CcSEcCtD
Ondansetron—Myocardial infarction—Bleomycin—skin cancer	0.00074	0.00307	CcSEcCtD
Ondansetron—Palpitations—Imiquimod—skin cancer	0.000733	0.00305	CcSEcCtD
Ondansetron—Loss of consciousness—Imiquimod—skin cancer	0.000729	0.00303	CcSEcCtD
Ondansetron—Cough—Imiquimod—skin cancer	0.000724	0.00301	CcSEcCtD
Ondansetron—Convulsion—Imiquimod—skin cancer	0.000719	0.00299	CcSEcCtD
Ondansetron—Chest pain—Imiquimod—skin cancer	0.000707	0.00293	CcSEcCtD
Ondansetron—Anxiety—Imiquimod—skin cancer	0.000704	0.00292	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000702	0.00291	CcSEcCtD
Ondansetron—Discomfort—Imiquimod—skin cancer	0.000698	0.0029	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.000698	0.0029	CcSEcCtD
Ondansetron—Dry mouth—Imiquimod—skin cancer	0.000691	0.00287	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000686	0.00285	CcSEcCtD
Ondansetron—Fatigue—Vemurafenib—skin cancer	0.000685	0.00284	CcSEcCtD
Ondansetron—Haemoglobin—Bleomycin—skin cancer	0.000681	0.00283	CcSEcCtD
Ondansetron—Constipation—Vemurafenib—skin cancer	0.000679	0.00282	CcSEcCtD
Ondansetron—Haemorrhage—Bleomycin—skin cancer	0.000677	0.00281	CcSEcCtD
Ondansetron—Dysuria—Temozolomide—skin cancer	0.000667	0.00277	CcSEcCtD
Ondansetron—Shock—Imiquimod—skin cancer	0.000666	0.00277	CcSEcCtD
Ondansetron—Nervous system disorder—Imiquimod—skin cancer	0.000664	0.00276	CcSEcCtD
Ondansetron—Tachycardia—Imiquimod—skin cancer	0.000661	0.00275	CcSEcCtD
Ondansetron—Skin disorder—Imiquimod—skin cancer	0.000658	0.00273	CcSEcCtD
Ondansetron—Angina pectoris—Fluorouracil—skin cancer	0.000641	0.00266	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000631	0.00262	CcSEcCtD
Ondansetron—Flushing—Bleomycin—skin cancer	0.000629	0.00261	CcSEcCtD
Ondansetron—Body temperature increased—Vemurafenib—skin cancer	0.000628	0.00261	CcSEcCtD
Ondansetron—Swelling—Docetaxel—skin cancer	0.000623	0.00259	CcSEcCtD
Ondansetron—Urinary tract infection—Temozolomide—skin cancer	0.000619	0.00257	CcSEcCtD
Ondansetron—Hepatic failure—Docetaxel—skin cancer	0.000611	0.00254	CcSEcCtD
Ondansetron—Paraesthesia—Imiquimod—skin cancer	0.000608	0.00253	CcSEcCtD
Ondansetron—Chills—Bleomycin—skin cancer	0.000608	0.00252	CcSEcCtD
Ondansetron—Dyspnoea—Imiquimod—skin cancer	0.000604	0.00251	CcSEcCtD
Ondansetron—Somnolence—Imiquimod—skin cancer	0.000602	0.0025	CcSEcCtD
Ondansetron—Hepatobiliary disease—Temozolomide—skin cancer	0.000602	0.0025	CcSEcCtD
Ondansetron—Erythema multiforme—Dactinomycin—skin cancer	0.000597	0.00248	CcSEcCtD
Ondansetron—Erythema—Bleomycin—skin cancer	0.00059	0.00245	CcSEcCtD
Ondansetron—Flushing—Dactinomycin—skin cancer	0.000586	0.00244	CcSEcCtD
Ondansetron—Hypersensitivity—Vemurafenib—skin cancer	0.000585	0.00243	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Imiquimod—skin cancer	0.000585	0.00243	CcSEcCtD
Ondansetron—Fatigue—Imiquimod—skin cancer	0.000584	0.00243	CcSEcCtD
Ondansetron—Atrial fibrillation—Docetaxel—skin cancer	0.00058	0.00241	CcSEcCtD
Ondansetron—Visual disturbance—Docetaxel—skin cancer	0.00058	0.00241	CcSEcCtD
Ondansetron—Pain—Imiquimod—skin cancer	0.000579	0.00241	CcSEcCtD
Ondansetron—Acute coronary syndrome—Fluorouracil—skin cancer	0.000578	0.0024	CcSEcCtD
Ondansetron—Myocardial infarction—Fluorouracil—skin cancer	0.000575	0.00239	CcSEcCtD
Ondansetron—Haemoglobin—Temozolomide—skin cancer	0.000574	0.00239	CcSEcCtD
Ondansetron—Haemorrhage—Temozolomide—skin cancer	0.000571	0.00237	CcSEcCtD
Ondansetron—Urinary tract infection—Fluorouracil—skin cancer	0.00057	0.00237	CcSEcCtD
Ondansetron—Asthenia—Vemurafenib—skin cancer	0.00057	0.00237	CcSEcCtD
Ondansetron—Chills—Dactinomycin—skin cancer	0.000567	0.00235	CcSEcCtD
Ondansetron—Pruritus—Vemurafenib—skin cancer	0.000562	0.00233	CcSEcCtD
Ondansetron—Feeling abnormal—Imiquimod—skin cancer	0.000558	0.00232	CcSEcCtD
Ondansetron—Gastrointestinal pain—Imiquimod—skin cancer	0.000554	0.0023	CcSEcCtD
Ondansetron—Visual impairment—Temozolomide—skin cancer	0.000551	0.00229	CcSEcCtD
Ondansetron—Erythema—Dactinomycin—skin cancer	0.00055	0.00228	CcSEcCtD
Ondansetron—Ill-defined disorder—Bleomycin—skin cancer	0.000547	0.00227	CcSEcCtD
Ondansetron—Diarrhoea—Vemurafenib—skin cancer	0.000543	0.00226	CcSEcCtD
Ondansetron—Erythema multiforme—Temozolomide—skin cancer	0.00054	0.00224	CcSEcCtD
Ondansetron—Urticaria—Imiquimod—skin cancer	0.000538	0.00224	CcSEcCtD
Ondansetron—Abdominal pain—Imiquimod—skin cancer	0.000535	0.00222	CcSEcCtD
Ondansetron—Body temperature increased—Imiquimod—skin cancer	0.000535	0.00222	CcSEcCtD
Ondansetron—Eye disorder—Temozolomide—skin cancer	0.000534	0.00222	CcSEcCtD
Ondansetron—Malaise—Bleomycin—skin cancer	0.000532	0.00221	CcSEcCtD
Ondansetron—Flushing—Temozolomide—skin cancer	0.00053	0.0022	CcSEcCtD
Ondansetron—Cardiac disorder—Temozolomide—skin cancer	0.00053	0.0022	CcSEcCtD
Ondansetron—Haemoglobin—Fluorouracil—skin cancer	0.000529	0.0022	CcSEcCtD
Ondansetron—Haemorrhage—Fluorouracil—skin cancer	0.000526	0.00219	CcSEcCtD
Ondansetron—Dizziness—Vemurafenib—skin cancer	0.000525	0.00218	CcSEcCtD
Ondansetron—Angiopathy—Temozolomide—skin cancer	0.000518	0.00215	CcSEcCtD
Ondansetron—Immune system disorder—Temozolomide—skin cancer	0.000516	0.00214	CcSEcCtD
Ondansetron—Mediastinal disorder—Temozolomide—skin cancer	0.000515	0.00214	CcSEcCtD
Ondansetron—Cough—Bleomycin—skin cancer	0.000515	0.00214	CcSEcCtD
Ondansetron—Chills—Temozolomide—skin cancer	0.000513	0.00213	CcSEcCtD
Ondansetron—Ill-defined disorder—Dactinomycin—skin cancer	0.00051	0.00212	CcSEcCtD
Ondansetron—Liver function test abnormal—Docetaxel—skin cancer	0.000507	0.00211	CcSEcCtD
Ondansetron—Vomiting—Vemurafenib—skin cancer	0.000505	0.0021	CcSEcCtD
Ondansetron—Chest pain—Bleomycin—skin cancer	0.000502	0.00209	CcSEcCtD
Ondansetron—Rash—Vemurafenib—skin cancer	0.000501	0.00208	CcSEcCtD
Ondansetron—Dermatitis—Vemurafenib—skin cancer	0.0005	0.00208	CcSEcCtD
Ondansetron—Hypersensitivity—Imiquimod—skin cancer	0.000499	0.00207	CcSEcCtD
Ondansetron—Headache—Vemurafenib—skin cancer	0.000498	0.00207	CcSEcCtD
Ondansetron—Erythema—Temozolomide—skin cancer	0.000497	0.00207	CcSEcCtD
Ondansetron—Discomfort—Bleomycin—skin cancer	0.000496	0.00206	CcSEcCtD
Ondansetron—Malaise—Dactinomycin—skin cancer	0.000496	0.00206	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000495	0.00205	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000495	0.00205	CcSEcCtD
Ondansetron—Asthenia—Imiquimod—skin cancer	0.000486	0.00202	CcSEcCtD
Ondansetron—Anaphylactic shock—Bleomycin—skin cancer	0.000481	0.002	CcSEcCtD
Ondansetron—Pruritus—Imiquimod—skin cancer	0.000479	0.00199	CcSEcCtD
Ondansetron—Arrhythmia—Fluorouracil—skin cancer	0.00047	0.00195	CcSEcCtD
Ondansetron—Vision blurred—Temozolomide—skin cancer	0.000469	0.00195	CcSEcCtD
Ondansetron—Bronchospasm—Docetaxel—skin cancer	0.000467	0.00194	CcSEcCtD
Ondansetron—Tremor—Temozolomide—skin cancer	0.000466	0.00194	CcSEcCtD
Ondansetron—Diarrhoea—Imiquimod—skin cancer	0.000463	0.00193	CcSEcCtD
Ondansetron—Discomfort—Dactinomycin—skin cancer	0.000463	0.00192	CcSEcCtD
Ondansetron—Angina pectoris—Docetaxel—skin cancer	0.000462	0.00192	CcSEcCtD
Ondansetron—Ill-defined disorder—Temozolomide—skin cancer	0.000461	0.00192	CcSEcCtD
Ondansetron—Erythema—Fluorouracil—skin cancer	0.000458	0.0019	CcSEcCtD
Ondansetron—Agitation—Temozolomide—skin cancer	0.000457	0.0019	CcSEcCtD
Ondansetron—Angioedema—Temozolomide—skin cancer	0.000454	0.00189	CcSEcCtD
Ondansetron—Hypotension—Bleomycin—skin cancer	0.00045	0.00187	CcSEcCtD
Ondansetron—Malaise—Temozolomide—skin cancer	0.000449	0.00186	CcSEcCtD
Ondansetron—Dizziness—Imiquimod—skin cancer	0.000448	0.00186	CcSEcCtD
Ondansetron—Palpitations—Temozolomide—skin cancer	0.00044	0.00183	CcSEcCtD
Ondansetron—Cough—Temozolomide—skin cancer	0.000434	0.0018	CcSEcCtD
Ondansetron—Paraesthesia—Bleomycin—skin cancer	0.000432	0.00179	CcSEcCtD
Ondansetron—Vision blurred—Fluorouracil—skin cancer	0.000432	0.00179	CcSEcCtD
Ondansetron—Convulsion—Temozolomide—skin cancer	0.000431	0.00179	CcSEcCtD
Ondansetron—Vomiting—Imiquimod—skin cancer	0.000431	0.00179	CcSEcCtD
Ondansetron—Dyspnoea—Bleomycin—skin cancer	0.000429	0.00178	CcSEcCtD
Ondansetron—Rash—Imiquimod—skin cancer	0.000427	0.00177	CcSEcCtD
Ondansetron—Dermatitis—Imiquimod—skin cancer	0.000427	0.00177	CcSEcCtD
Ondansetron—Headache—Imiquimod—skin cancer	0.000424	0.00176	CcSEcCtD
Ondansetron—Anxiety—Temozolomide—skin cancer	0.000422	0.00175	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000421	0.00175	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.00042	0.00174	CcSEcCtD
Ondansetron—Discomfort—Temozolomide—skin cancer	0.000418	0.00174	CcSEcCtD
Ondansetron—Acute coronary syndrome—Docetaxel—skin cancer	0.000417	0.00173	CcSEcCtD
Ondansetron—Myocardial infarction—Docetaxel—skin cancer	0.000415	0.00172	CcSEcCtD
Ondansetron—Dry mouth—Temozolomide—skin cancer	0.000414	0.00172	CcSEcCtD
Ondansetron—Pain—Bleomycin—skin cancer	0.000412	0.00171	CcSEcCtD
Ondansetron—Anaphylactic shock—Temozolomide—skin cancer	0.000406	0.00169	CcSEcCtD
Ondansetron—Hepatobiliary disease—Docetaxel—skin cancer	0.0004	0.00166	CcSEcCtD
Ondansetron—Nervous system disorder—Temozolomide—skin cancer	0.000398	0.00165	CcSEcCtD
Ondansetron—Convulsion—Fluorouracil—skin cancer	0.000397	0.00165	CcSEcCtD
Ondansetron—Feeling abnormal—Bleomycin—skin cancer	0.000397	0.00165	CcSEcCtD
Ondansetron—Skin disorder—Temozolomide—skin cancer	0.000394	0.00164	CcSEcCtD
Ondansetron—Chest pain—Fluorouracil—skin cancer	0.00039	0.00162	CcSEcCtD
Ondansetron—Fatigue—Dactinomycin—skin cancer	0.000387	0.00161	CcSEcCtD
Ondansetron—Discomfort—Fluorouracil—skin cancer	0.000385	0.0016	CcSEcCtD
Ondansetron—Pain—Dactinomycin—skin cancer	0.000384	0.00159	CcSEcCtD
Ondansetron—Urticaria—Bleomycin—skin cancer	0.000382	0.00159	CcSEcCtD
Ondansetron—Haemoglobin—Docetaxel—skin cancer	0.000382	0.00159	CcSEcCtD
Ondansetron—Body temperature increased—Bleomycin—skin cancer	0.00038	0.00158	CcSEcCtD
Ondansetron—Haemorrhage—Docetaxel—skin cancer	0.00038	0.00158	CcSEcCtD
Ondansetron—Anaphylactic shock—Fluorouracil—skin cancer	0.000374	0.00155	CcSEcCtD
Ondansetron—Feeling abnormal—Dactinomycin—skin cancer	0.00037	0.00154	CcSEcCtD
Ondansetron—Gastrointestinal pain—Dactinomycin—skin cancer	0.000367	0.00152	CcSEcCtD
Ondansetron—Nervous system disorder—Fluorouracil—skin cancer	0.000367	0.00152	CcSEcCtD
Ondansetron—Visual impairment—Docetaxel—skin cancer	0.000366	0.00152	CcSEcCtD
Ondansetron—Tachycardia—Fluorouracil—skin cancer	0.000365	0.00152	CcSEcCtD
Ondansetron—Paraesthesia—Temozolomide—skin cancer	0.000364	0.00151	CcSEcCtD
Ondansetron—Dyspnoea—Temozolomide—skin cancer	0.000362	0.0015	CcSEcCtD
Ondansetron—Somnolence—Temozolomide—skin cancer	0.000361	0.0015	CcSEcCtD
Ondansetron—Erythema multiforme—Docetaxel—skin cancer	0.000359	0.00149	CcSEcCtD
Ondansetron—Eye disorder—Docetaxel—skin cancer	0.000355	0.00147	CcSEcCtD
Ondansetron—Abdominal pain—Dactinomycin—skin cancer	0.000355	0.00147	CcSEcCtD
Ondansetron—Body temperature increased—Dactinomycin—skin cancer	0.000355	0.00147	CcSEcCtD
Ondansetron—Hypersensitivity—Bleomycin—skin cancer	0.000355	0.00147	CcSEcCtD
Ondansetron—Flushing—Docetaxel—skin cancer	0.000353	0.00146	CcSEcCtD
Ondansetron—Cardiac disorder—Docetaxel—skin cancer	0.000353	0.00146	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Temozolomide—skin cancer	0.00035	0.00146	CcSEcCtD
Ondansetron—Fatigue—Temozolomide—skin cancer	0.00035	0.00145	CcSEcCtD
Ondansetron—Hypotension—Fluorouracil—skin cancer	0.000349	0.00145	CcSEcCtD
Ondansetron—Pain—Temozolomide—skin cancer	0.000347	0.00144	CcSEcCtD
Ondansetron—Constipation—Temozolomide—skin cancer	0.000347	0.00144	CcSEcCtD
Ondansetron—Asthenia—Bleomycin—skin cancer	0.000345	0.00143	CcSEcCtD
Ondansetron—Angiopathy—Docetaxel—skin cancer	0.000345	0.00143	CcSEcCtD
Ondansetron—Immune system disorder—Docetaxel—skin cancer	0.000343	0.00143	CcSEcCtD
Ondansetron—Mediastinal disorder—Docetaxel—skin cancer	0.000342	0.00142	CcSEcCtD
Ondansetron—Chills—Docetaxel—skin cancer	0.000341	0.00142	CcSEcCtD
Ondansetron—Pruritus—Bleomycin—skin cancer	0.00034	0.00141	CcSEcCtD
Ondansetron—Arrhythmia—Docetaxel—skin cancer	0.000339	0.00141	CcSEcCtD
Ondansetron—Paraesthesia—Fluorouracil—skin cancer	0.000336	0.00139	CcSEcCtD
Ondansetron—Feeling abnormal—Temozolomide—skin cancer	0.000334	0.00139	CcSEcCtD
Ondansetron—Dyspnoea—Fluorouracil—skin cancer	0.000333	0.00139	CcSEcCtD
Ondansetron—Somnolence—Fluorouracil—skin cancer	0.000332	0.00138	CcSEcCtD
Ondansetron—Gastrointestinal pain—Temozolomide—skin cancer	0.000332	0.00138	CcSEcCtD
Ondansetron—Erythema—Docetaxel—skin cancer	0.000331	0.00137	CcSEcCtD
Ondansetron—Hypersensitivity—Dactinomycin—skin cancer	0.000331	0.00137	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000323	0.00134	CcSEcCtD
Ondansetron—Urticaria—Temozolomide—skin cancer	0.000322	0.00134	CcSEcCtD
Ondansetron—Asthenia—Dactinomycin—skin cancer	0.000322	0.00134	CcSEcCtD
Ondansetron—Abdominal pain—Temozolomide—skin cancer	0.000321	0.00133	CcSEcCtD
Ondansetron—Body temperature increased—Temozolomide—skin cancer	0.000321	0.00133	CcSEcCtD
Ondansetron—Pain—Fluorouracil—skin cancer	0.00032	0.00133	CcSEcCtD
Ondansetron—Feeling abnormal—Fluorouracil—skin cancer	0.000308	0.00128	CcSEcCtD
Ondansetron—Diarrhoea—Dactinomycin—skin cancer	0.000307	0.00128	CcSEcCtD
Ondansetron—Vomiting—Bleomycin—skin cancer	0.000306	0.00127	CcSEcCtD
Ondansetron—Rash—Bleomycin—skin cancer	0.000303	0.00126	CcSEcCtD
Ondansetron—Dermatitis—Bleomycin—skin cancer	0.000303	0.00126	CcSEcCtD
Ondansetron—Hypersensitivity—Temozolomide—skin cancer	0.000299	0.00124	CcSEcCtD
Ondansetron—Urticaria—Fluorouracil—skin cancer	0.000297	0.00123	CcSEcCtD
Ondansetron—Syncope—Docetaxel—skin cancer	0.000297	0.00123	CcSEcCtD
Ondansetron—Body temperature increased—Fluorouracil—skin cancer	0.000296	0.00123	CcSEcCtD
Ondansetron—Palpitations—Docetaxel—skin cancer	0.000292	0.00121	CcSEcCtD
Ondansetron—Asthenia—Temozolomide—skin cancer	0.000291	0.00121	CcSEcCtD
Ondansetron—Loss of consciousness—Docetaxel—skin cancer	0.000291	0.00121	CcSEcCtD
Ondansetron—Cough—Docetaxel—skin cancer	0.000289	0.0012	CcSEcCtD
Ondansetron—Pruritus—Temozolomide—skin cancer	0.000287	0.00119	CcSEcCtD
Ondansetron—Convulsion—Docetaxel—skin cancer	0.000287	0.00119	CcSEcCtD
Ondansetron—Vomiting—Dactinomycin—skin cancer	0.000285	0.00119	CcSEcCtD
Ondansetron—Rash—Dactinomycin—skin cancer	0.000283	0.00118	CcSEcCtD
Ondansetron—Chest pain—Docetaxel—skin cancer	0.000282	0.00117	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00028	0.00116	CcSEcCtD
Ondansetron—Diarrhoea—Temozolomide—skin cancer	0.000278	0.00115	CcSEcCtD
Ondansetron—Hypersensitivity—Fluorouracil—skin cancer	0.000276	0.00114	CcSEcCtD
Ondansetron—Dry mouth—Docetaxel—skin cancer	0.000275	0.00114	CcSEcCtD
Ondansetron—Anaphylactic shock—Docetaxel—skin cancer	0.00027	0.00112	CcSEcCtD
Ondansetron—Dizziness—Temozolomide—skin cancer	0.000268	0.00111	CcSEcCtD
Ondansetron—Shock—Docetaxel—skin cancer	0.000266	0.0011	CcSEcCtD
Ondansetron—Nervous system disorder—Docetaxel—skin cancer	0.000265	0.0011	CcSEcCtD
Ondansetron—Pruritus—Fluorouracil—skin cancer	0.000265	0.0011	CcSEcCtD
Ondansetron—Tachycardia—Docetaxel—skin cancer	0.000263	0.00109	CcSEcCtD
Ondansetron—Skin disorder—Docetaxel—skin cancer	0.000262	0.00109	CcSEcCtD
Ondansetron—Vomiting—Temozolomide—skin cancer	0.000258	0.00107	CcSEcCtD
Ondansetron—Rash—Temozolomide—skin cancer	0.000256	0.00106	CcSEcCtD
Ondansetron—Diarrhoea—Fluorouracil—skin cancer	0.000256	0.00106	CcSEcCtD
Ondansetron—Dermatitis—Temozolomide—skin cancer	0.000256	0.00106	CcSEcCtD
Ondansetron—Headache—Temozolomide—skin cancer	0.000254	0.00106	CcSEcCtD
Ondansetron—Hypotension—Docetaxel—skin cancer	0.000252	0.00105	CcSEcCtD
Ondansetron—Dizziness—Fluorouracil—skin cancer	0.000247	0.00103	CcSEcCtD
Ondansetron—Paraesthesia—Docetaxel—skin cancer	0.000242	0.00101	CcSEcCtD
Ondansetron—Dyspnoea—Docetaxel—skin cancer	0.000241	0.001	CcSEcCtD
Ondansetron—Somnolence—Docetaxel—skin cancer	0.00024	0.000997	CcSEcCtD
Ondansetron—Vomiting—Fluorouracil—skin cancer	0.000238	0.000988	CcSEcCtD
Ondansetron—Rash—Fluorouracil—skin cancer	0.000236	0.00098	CcSEcCtD
Ondansetron—Dermatitis—Fluorouracil—skin cancer	0.000236	0.000979	CcSEcCtD
Ondansetron—Headache—Fluorouracil—skin cancer	0.000234	0.000973	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Docetaxel—skin cancer	0.000233	0.000968	CcSEcCtD
Ondansetron—Fatigue—Docetaxel—skin cancer	0.000233	0.000967	CcSEcCtD
Ondansetron—Pain—Docetaxel—skin cancer	0.000231	0.000959	CcSEcCtD
Ondansetron—Constipation—Docetaxel—skin cancer	0.000231	0.000959	CcSEcCtD
Ondansetron—Feeling abnormal—Docetaxel—skin cancer	0.000222	0.000924	CcSEcCtD
Ondansetron—Gastrointestinal pain—Docetaxel—skin cancer	0.000221	0.000917	CcSEcCtD
Ondansetron—Abdominal pain—Docetaxel—skin cancer	0.000213	0.000886	CcSEcCtD
Ondansetron—Body temperature increased—Docetaxel—skin cancer	0.000213	0.000886	CcSEcCtD
Ondansetron—Hypersensitivity—Docetaxel—skin cancer	0.000199	0.000826	CcSEcCtD
Ondansetron—Asthenia—Docetaxel—skin cancer	0.000194	0.000804	CcSEcCtD
Ondansetron—Pruritus—Docetaxel—skin cancer	0.000191	0.000793	CcSEcCtD
Ondansetron—Diarrhoea—Docetaxel—skin cancer	0.000185	0.000767	CcSEcCtD
Ondansetron—Dizziness—Docetaxel—skin cancer	0.000179	0.000741	CcSEcCtD
Ondansetron—Vomiting—Docetaxel—skin cancer	0.000172	0.000713	CcSEcCtD
Ondansetron—Rash—Docetaxel—skin cancer	0.00017	0.000707	CcSEcCtD
Ondansetron—Dermatitis—Docetaxel—skin cancer	0.00017	0.000706	CcSEcCtD
Ondansetron—Headache—Docetaxel—skin cancer	0.000169	0.000702	CcSEcCtD
